{"type":"trials","record":{"id":42096,"source_id":"clinicaltrials-gov","external_id":"NCT05259371","title":"Study of Application of Transcutaneous Pulsed Electrical Stimulation Around Eye in Age-related Macular Degeneration","brief_summary":"This study aims to evaluate the safety and efficacy of applying pulse electrical stimulation around eyes of age-related macular patients.","overall_status":"Unknown","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Nu Eyne Co., Ltd.","enrollment":25,"countries":["South Korea"],"start_date":"2022-10-05","completion_date":"2024-06-30","last_update_date":"2023-09-11","source_url":"https://clinicaltrials.gov/study/NCT05259371","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Nu Eyne Co., Ltd.","interventions":["Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Safety Events — baseline ~ 16 weeks","Changes in contrast sensitivity — baseline, 6, 16 weeks","Changes in score of VFQ-25(National Eye Institute) — baseline, 6, 16 weeks","Changes in best corrected visual acuity(Early Treatment Diabetic Retinopathy Study (ETDRS) Chart) — baseline, 6, 16 wee…","Changes in drusen area using optical coherence tomography(OCT) — baseline, 6, 16 weeks","Changes in drusen volume using optical coherence tomography(OCT) — baseline, 6, 16 weeks","Progression to advanced Age-related Macular Degeneration (AMD) using fundus autofluorescence(FAF) — baseline, 6, 16 wee…","Progression to advanced Age-related Macular Degeneration (AMD) using fundus photography — baseline, 6, 16 weeks"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Early to Moderate Dry Age-Related Macular Degeneration","Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05259371","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-10-05 to 2024-06-30","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.919Z","intervention":["Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)"],"participants":25,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Safety Events — baseline ~ 16 weeks","Changes in contrast sensitivity — baseline, 6, 16 weeks","Changes in score of VFQ-25(National Eye Institute) — baseline, 6, 16 weeks","Changes in best corrected visual acuity(Early Treatment Diabetic Retinopathy Study (ETDRS) Chart) — baseline, 6, 16 wee…","Changes in drusen area using optical coherence tomography(OCT) — baseline, 6, 16 weeks","Changes in drusen volume using optical coherence tomography(OCT) — baseline, 6, 16 weeks","Progression to advanced Age-related Macular Degeneration (AMD) using fundus autofluorescence(FAF) — baseline, 6, 16 wee…","Progression to advanced Age-related Macular Degeneration (AMD) using fundus photography — baseline, 6, 16 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42096","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}